Meet Inspiring Speakers and Experts at our 3000+ Global Events with over 1000+ Conferences, 1000+ Symposiums and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World’s leading Event Organizer

Conference Series Conferences gaining more Readers and Visitors

Conference Series Web Metrics at a Glance

  • 3000+ Global Events
  • 100 Million+ Visitors
  • 75000+ Unique visitors per conference
  • 100000+ Page views for every individual conference

Unique Opportunity! Online visibility to the Speakers and Experts

Tuberculosis 2023

About Conference

Tuberculosis 2023 takes immense pleasure to welcome you to join “5th World Congress on Tuberculosis and lung Diseases”, which is organized at  Singapore City, Singapore during August 07-08, 2023. The main aim of the conference is to unite a one of a gentle and worldwide assortment of vast, moderate & therapeutic clinical research formations and demonstrative organizations.

Tuberculosis 2023 melds brief Essential presentations, Speaker talks, Exhibition, Meetings and Workshops. It will upturn the most vibrant and latest issues in the field of TB & Lung Diseases. The best part of the conference include Epidemiology of TB, Drug discovery and development in TB, MDR-TB, Tuberculosis-HIV co-infection, Tuberculosis and rehabilitation, Nanotechnology Approach in TB etc., are just a few of the many fields in which it has applications.

Why to attend?

With folks all over the world concentrated on discovering TB, Lung diseases and related fields, this is the outright best chance of getting the major assemblage of TB & Lung diseases group members. Host workshops, distribute data, meet recent and potential handlers, sprinkling one more product offering, and earn name appreciation on this two-day opportunity.


  • All accepted abstracts will be published in the supporting  journals of the conference and Conference Book Records.
  • Each abstract will get a DOI number provided by Cross Ref.
  • Chance to conduct Workshop with your team participants.
  • One to one interface with Keynote Speakers, OCM and Renowned personalities for the future course of work.
  • Opportunity to head a session.
  • Certification by the establishing committee.
  • Distinct keynote Page will be created to get more prominence for your scientific research.
  • Huge Profits on Group Registration and much more.

Target Audience:

Delegates , Research scholars
New entrepreneurs
Immense industrialists
Principal investigator and desire makers from all corners of Tuberculosis & Lung Diseases.
Directors and CEO's of research-based completely organizations whore making funding in TB at some stage in the globe.


Sessions/ Tracks

Track 01: Tuberculosis

Infectious illnesses such as tuberculosis are typically caused by MTB germs (Mycobacterium tuberculosis). In addition to affecting the lungs, can also cause harm to other organs. Latent tuberculosis occurs when an infection is not diagnosed. If untreated, almost half of people with active disease—which develops from around 10% of latent infections—die. An active TB infection is characterized by chronic coughs with bloody mucus, fever, night sweats, and weight loss.

Track 02: Epidemiology of TB

One of the most widespread infections in the world is tuberculosis. M.tuberculosis infection affects an estimated 2 billion individuals, or about one-fourth of the world's population. Approximately 10 million individuals get TB disease each year, and 1.6 million people pass away from it. In actuality, the world's most common infectious disease-related cause of mortality is tuberculosis (TB).

Track 03: Drug discovery and development in TB

Fighting the global tuberculosis (TB) for the development of new, more potent antibiotics that inhibit Mycobacterium tuberculosis' critical proteins. The main goal of drug design and discovery is to identify a chemical that can specifically target a specific cavity in a protein and prevent it from engaging in its enzymatic function. A variety of studies, including clinical trials, are subsequently performed on the substance in question to determine how well it works to combat the infection inside the host. Recently, as opposed to the tedious and time-consuming old methods of drug design, new strategies that involve computational and analytical methodologies have improved the odds of drug discovery.

A new generation of software that is utilized to create and optimize active compounds that can be used in chemotherapeutic research in the future to tackle global tuberculosis resistance has improved computational methodologies in drug creation.

Track 04: Multi Drug resistant Tuberculosis (MDR-TB)
MDR tuberculosis is caused by bacteria that are resistant to both of the most effective TB medications. All people with TB illness are treated with these medications.

Track 05: Tuberculosis-HIV Co-infection

HIV/TB coinfection is the combination of HIV and TB infection. Those with HIV have a higher risk of developing TB disease from an untreated latent TB infection than do people without HIV. TB illness is regarded as an AIDS-defining condition in patients with HIV.Conditions that constitute AIDS include infections and cancers that provide a life-threatening hazard to HIV-positive people.

HIV treatment is referred to as antiretroviral therapy (ART). HIV medications boost the immune system, preventing the spread of HIV and AIDS-related illnesses (AIDS). Treatment with HIV and TB medications minimizes the likelihood that latent TB infection may progress to TB illness in patients with HIV and latent TB infection.

Track 06: Tuberculosis and rehabilitation

Patients who recover from TB frequently experience chronic sequelae, which might cause their lung function to further deteriorate. For "cured" individuals with compromised lung function who require pulmonary rehabilitation, there is still little guidance available. Given that recent studies have demonstrated the positive effects of pulmonary rehabilitation for TB patients, additional tests for evaluation should be administered following the end of treatment.

Track 07 : Nanotechnology approach in TB

Numerous nanotechnology-based methods for treating tuberculosis are discussed in the book Nanotechnology Based Approaches for Tuberculosis Treatment, which could aid in overcoming the still-present drawbacks of conventional and traditional methods. The most significant administration routes are covered together with the varieties of nanodrugs, their manufacture, formulation, characterisation, and uses. Additionally, it examines current research and accomplishments in therapeutic efficacy and offers potential applications for the future. It will be a helpful tool for scientists, inventors, pharmaceutical researchers, and researchers working on tailored medicines, nanoscale imaging systems, and tuberculosis diagnostic methods.

Track 08 : Diagnosis and treatment of Tuberculosis


Physical examinations include a stethoscope listening to your lungs and checking your lymph nodes for swelling.
Tuberculosis is still mostly diagnosed through skin tests, but blood tests are becoming more common. Injection of tuberculin is performed under the skin of the forearm. Only a tiny needle prick should be felt by you.

A medical practitioner will examine your arm to look for swelling at the injection site within 48 to 72 hours. If you have a hard, raised red bump, you most certainly have TB infection. The significance of the test results depends on the size of the bump.

Active TB

Active tuberculosis is difficult to detect solely based on signs and symptoms, and it is even more difficult to diagnose the condition in those with weakened immune systems. However, those who display lung illness symptoms or persistent constitutional symptoms that last more than two weeks need to be tested for TB. An X-ray of the chest and numerous sputum cultures for acid-fast bacilli are frequently done as part of the initial examination. In the majority of the developing world, interferon-release assays and tuberculin skin tests are not very useful. In people with HIV, interferon gamma release tests (IGRA) have comparable restrictions.

Latent TB

Latent TB has no symptoms Does not feel sick, Cannot spread TB bacteria to others, Usually has a skin test or blood test result indicating TB infection, Has a normal chest x-ray and a negative sputum smear, Needs treatment for latent TB infection to prevent TB disease.

If you have latent TB and are at a high risk of developing active TB, your doctor may advise pharmaceutical treatment. Active tuberculosis requires antibiotic treatment for six to nine months.
The type of medication you receive and the length of your treatment will depend on your age, general health, drug resistance potential, and the location of the infection in your body.

Track 09: TB Prevention

Many persons with latent TB infection never experience the symptoms of TB illness. However, some people with latent TB infection are more prone than others to acquire TB illness. High-risk individuals for TB disease development include:

people who are HIV-positive, Those who have just had TB infection during the last two years, Infants and young kids, Those who inject illegal drugs Those who suffer from illnesses that compromise their immune systems, Older individuals, People who in the past received improper TB treatment.

If you have latent TB infection and fall into one of these categories, you should take medication to prevent getting sick with TB. For latent tuberculosis infection, there are numerous therapy options. Which treatment is best for you must be decided by both you and your healthcare practitioner. It can prevent you from contracting TB disease if you take your medication as directed. Treatment for latent TB infection is more simpler than treatment for active TB disease since there are less germs present. The body of a person with TB disease has a lot of TB bacteria. To treat TB disease, numerous medications are required.

Track 10: Pulmonary disease and lung cancer

The lungs' airways and other pulmonary structures are affected by CRDs. The most common ones include chronic obstructive pulmonary disease, Air pollution, exposure to chemicals and dusts at work, and recurrent lower respiratory infections in children are other risk factors in addition to tobacco smoke. Although CRDs cannot be cured, there are numerous treatments that can assist expand the airways and reduce shortness of breath, which can help control symptoms and enhance everyday life for persons with these disorders.

Lung cancer can also deveop in lymph nodes and in other body organs. Such as the brain. There are potential risks associated with lung cancer spreading to other organs. A metastasis is the spread of cancer cells between organs.

Small cell and non-small cell lung tumors are the two primary subtypes that are typically recognised (including adenocarcinoma and squamous cell carcinoma). Various therapies are available to treat these different types of lung cancer. It is more common to develop non small cell lung cancer than small cell lung cancer.

Track 11: Interstitial lung disease

The term "Interstitial lung disease" (ILD) refers to a number of disorders that result in lung inflammation and scarring. Shortness of breath and a dry cough are ILD symptoms. Medication, radiation therapy, connective tissue conditions, as well as breathing dangerous substances, can all contribute to ILD. ILD frequently results in irreparable lung damage.

Track 12: Chronic obstructive pulmonary disease

The progressive lung condition known as chronic obstructive pulmonary disease (COPD) is characterized by persistent respiratory symptoms and restricted airflow. Breathlessness and a cough that may or may not produce mucus are the prominent symptoms. Getting dressed or walking becomes harder as COPD worsens. Although COPD is incurable, it can be avoided and treated.
Emphysema and chronic bronchitis are the two diseases that cause COPD the most frequently.

Track 13: Neonatal lung disease

The lungs of a newborn cannot produce enough oxygen when they are not fully developed, resulting in newborn respiratory distress syndrome (NRDS). Premature infants are generally affected.
The condition is also commonly known as infant respiratory distress syndrome, hyaline membrane disease, and surfactant deficient lung disease.

Track 14: Lung infections

When a virus or bacteria that causes sickness damages and inflames the lungs, it is said to have a lung infection. This occurs as immune cells rush to the lungs' airways or lung tissue to battle the infection.
Viral, bacterial, fungal, parasitic, or fungal infections of the lungs are possible (though this is rare in the United States). There are many types of microbes that can cause lung infections. For instance, bacterial pneumonia might result from viral bronchitis.

Track 15: Lung Transplantation

A surgical surgery known as a lung transplant, sometimes known as a pulmonary transplant, replaces one or both of the patient's own lungs with donor lungs. Both living and deceased donors can provide donor lungs for transplant. One lung lobe can only be donated by a living person. One lung may be sufficient for a recipient with certain lung conditions. A recipient must get two lungs if they have cystic fibrosis or another lung condition. Although lung transplants have some potential hazards, they can also help people with end-stage pulmonary illness live longer and have better quality of life.

Track 16: Current and Future Trends in Tuberculosis

Especially in developing countries, tuberculosis is a serious health problem that increases chronic morbidity. The key to preventing future problems and limiting the spread of illness in the community is early identification and effective treatment. This overview addresses the many diagnostic techniques, including both traditional and more recent molecular techniques, as well as their benefits and drawbacks. There isn't a single test that can be deemed sensitive, trustworthy, quick, and cost-effective. To guarantee a quick and accurate diagnosis that would allow the clinician to deliver an effective treatment, a number of tests must be run.


Market Analysis

In 2021, the market for TB diagnostics was estimated to be worth USD 1.71 billion. The market is anticipated to expand at a CAGR of 6.1% from 2022 to 2029, rising from USD 2.07 billion in 2022 to USD 3.13 billion. The COVID-19 pandemic has had an unprecedented and shattering impact on the world, and demand for tuberculosis diagnostics has been lower than expected in all regions compared to pre-pandemic levels. Our investigation revealed that the global market had a decline of -21.5% in 2020 compared to 2019.
The severe bacterial infection tuberculosis is brought on by Mycobacterium tuberculosis. Usually, the sickness affects the patient's lungs. Along with other body parts, the infection can potentially harm the spine and the brain. The diagnosis of tuberculosis can be made through blood and skin tests.

Tuberculosis 2023 conferences

As the prevalence of this disorder has grown, so has the need for accurate and reliable diagnostic tests to halt its spread. This factor is expected to significantly raise demand for tuberculosis tests in the coming years.
The rise of the tuberculosis diagnostics market is related to rising TB incidences, rising illness awareness, and rising demand for tuberculosis diagnostics to reduce the burden of the disease. Additionally, the market growth has been boosted by the industry players' increased attention on getting their products approved and commercialized for TB diagnostics.

To Collaborate Scientific Professionals around the World

Conference Date August 07-08, 2023

For Sponsors & Exhibitors

Speaker Opportunity

Past Conference Report

Supported By

Journal of Lung Diseases & Treatment Pulmonary & Respiratory Medicine Journal of Tuberculosis and Therapeutics

All accepted abstracts will be published in respective Conference Series International Journals.

Abstracts will be provided with Digital Object Identifier by